MX349947B - Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada. - Google Patents

Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.

Info

Publication number
MX349947B
MX349947B MX2014001306A MX2014001306A MX349947B MX 349947 B MX349947 B MX 349947B MX 2014001306 A MX2014001306 A MX 2014001306A MX 2014001306 A MX2014001306 A MX 2014001306A MX 349947 B MX349947 B MX 349947B
Authority
MX
Mexico
Prior art keywords
methods
clostridial toxin
treating chronic
modified clostridial
neurogenic inflammation
Prior art date
Application number
MX2014001306A
Other languages
English (en)
Inventor
Gaxiola Meza Gustavo
Aguilar Enriquez Ivan
Paz Padilla Gilberto
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX349947B publication Critical patent/MX349947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a método para prolongar el tiempo de clímax en un paciente con necesidad del mismo, como son los métodos para tratar la eyaculación precoz mediante la administración local de una neurotoxina clostridial, tal como una neurotoxina botulínica, al paciente.
MX2014001306A 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada. MX349947B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/548,073 US8147848B2 (en) 2009-08-26 2009-08-26 Method for treating premature ejaculation with a botulinum neurotoxin
PCT/US2010/044959 WO2011028371A1 (en) 2009-08-26 2010-08-10 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin

Publications (1)

Publication Number Publication Date
MX349947B true MX349947B (es) 2017-08-22

Family

ID=43127150

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012002378A MX2012002378A (es) 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.
MX2014001306A MX349947B (es) 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012002378A MX2012002378A (es) 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.

Country Status (18)

Country Link
US (8) US8147848B2 (es)
EP (2) EP2470202B1 (es)
JP (2) JP5766699B2 (es)
KR (1) KR101612988B1 (es)
CN (2) CN102802663B (es)
AU (2) AU2010289969B2 (es)
BR (1) BR112012004246A2 (es)
CA (1) CA2772372C (es)
CY (1) CY1114792T1 (es)
DK (2) DK2470202T3 (es)
ES (2) ES2446969T3 (es)
IN (1) IN2012DN02210A (es)
MX (2) MX2012002378A (es)
PL (1) PL2470202T3 (es)
PT (1) PT2470202E (es)
RU (1) RU2568844C2 (es)
SI (1) SI2470202T1 (es)
WO (1) WO2011028371A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20120251518A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20130066148A1 (en) * 2011-09-12 2013-03-14 Kang Seon Cho Method of augmenting glans
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
AU2013246882B2 (en) 2012-04-13 2017-10-19 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin
EP3188706B1 (en) * 2014-09-02 2019-10-09 American Silver, LLC Botulinum toxin and colloidal silver particles
RU2565104C1 (ru) * 2014-10-24 2015-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения преждевременной эякуляции
WO2018213710A1 (en) * 2017-05-18 2018-11-22 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
WO2018220232A1 (en) * 2017-06-02 2018-12-06 Universite De Versailles-St Quentin En Yvelines Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction
US12102556B2 (en) 2022-05-31 2024-10-01 Max Azevedo System and method for fallopian birth control
US12337014B1 (en) 2024-06-17 2025-06-24 Enrico Guarino Intracavernosal gel infusion system with neurotoxin modulation for erectile function

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
ES2159624T3 (es) 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CN1123680A (zh) * 1994-11-18 1996-06-05 吕建京 一种对于肺脾肾虚有良好功效的保健品及其制造方法
EP1658858B2 (en) 1997-07-15 2014-03-26 The Regents of the University of Colorado Use of botulinum toxin for the treatment of recalcitrant voiding dysfunction
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
CN1146866C (zh) * 1998-11-17 2004-04-21 阿尔卑斯电气株式会社 浮起式磁头的冠顶形成方法及冠顶形成装置
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
RU2180591C2 (ru) * 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
CA2758923A1 (en) 2001-03-16 2002-09-26 Dmi Biosciences, Inc. Use of tramadol to delay ejaculation
JP2004531506A (ja) 2001-03-29 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
DE60323332D1 (de) * 2002-01-25 2008-10-16 Modular Properties Ltd Verfahren und zusammensetzungen zur behandlung der männlichen erektionsstörung
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
TW200418838A (en) * 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
US20070264373A1 (en) * 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
US20060100584A1 (en) 2004-08-10 2006-05-11 Orest Olejnik Needleless microprotrusion elastoplast system
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CN1682810A (zh) * 2005-02-22 2005-10-19 黄资源 一种治疗前列腺疾病的前列外敷散
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1948230A4 (en) 2005-11-17 2010-03-10 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULIN TOXINES WITH A REDUCED NUMBER OF NON-TOXIC PROTEINS
US7445783B2 (en) 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US20090005319A1 (en) * 2007-07-01 2009-01-01 Barone Jr Frank V Topical compositions for delaying ejaculation and methods of using the same
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
AU2008316989A1 (en) 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US9049616B2 (en) 2012-03-29 2015-06-02 Broadcom Corporation Session recovery after network coordinator or AP restart for single user, multiple user, multiple access, and/or MIMO wireless communications
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin

Also Published As

Publication number Publication date
JP2015163654A (ja) 2015-09-10
BR112012004246A2 (pt) 2016-04-05
RU2568844C2 (ru) 2015-11-20
US20130059789A1 (en) 2013-03-07
WO2011028371A1 (en) 2011-03-10
PT2470202E (pt) 2014-02-24
US9907841B2 (en) 2018-03-06
HK1171658A1 (en) 2013-04-05
ES2564677T3 (es) 2016-03-28
DK2708239T3 (en) 2016-03-14
IN2012DN02210A (es) 2015-08-21
US20150064167A1 (en) 2015-03-05
CY1114792T1 (el) 2016-12-14
DK2470202T3 (da) 2014-01-27
AU2010289969A1 (en) 2012-03-22
AU2015213381A1 (en) 2015-09-03
US20140140981A1 (en) 2014-05-22
US9186395B2 (en) 2015-11-17
KR101612988B1 (ko) 2016-04-15
US8617570B2 (en) 2013-12-31
JP5766699B2 (ja) 2015-08-19
CN103816530B (zh) 2016-12-07
CA2772372C (en) 2016-07-12
SI2470202T1 (sl) 2014-02-28
CN102802663B (zh) 2014-03-19
RU2012110324A (ru) 2013-10-10
US20160067319A1 (en) 2016-03-10
ES2446969T3 (es) 2014-03-11
JP6078108B2 (ja) 2017-02-08
EP2470202A1 (en) 2012-07-04
US9457069B2 (en) 2016-10-04
EP2708239B1 (en) 2015-12-09
US20120148563A1 (en) 2012-06-14
US20110052636A1 (en) 2011-03-03
EP2470202B1 (en) 2013-12-18
CN103816530A (zh) 2014-05-28
US20180185460A1 (en) 2018-07-05
JP2013503165A (ja) 2013-01-31
AU2015213381B2 (en) 2017-05-25
HK1194292A1 (en) 2014-10-17
PL2470202T3 (pl) 2014-05-30
EP2708239A1 (en) 2014-03-19
US8329193B2 (en) 2012-12-11
MX2012002378A (es) 2012-06-28
US8147848B2 (en) 2012-04-03
CA2772372A1 (en) 2011-03-10
US10420823B2 (en) 2019-09-24
US20170020997A1 (en) 2017-01-26
AU2010289969B2 (en) 2015-05-14
US8916177B2 (en) 2014-12-23
KR20120103760A (ko) 2012-09-19
CN102802663A (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
MX349947B (es) Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.
MX351448B (es) Enzimas de clostridium histolyticum y métodos para el uso de los mismos.
WO2012047733A3 (en) Treatment of acne by conditioned media
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
AU2010236286A8 (en) Modulation of inflammatory responses by Factor XI
IL205280A0 (en) Methods of treating chronic neurogenic inflammation using modified clostridial toxins
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
SG10201804809RA (en) Clostridium difficile antibodies
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
WO2010138395A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
MX2010003371A (es) Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
EA201491418A1 (ru) Рекомбинантные микроорганизмы и способы их применения
WO2010138379A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2013006490A3 (en) Antibodies that specifically bind to tim3
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
MX359854B (es) Anticuerpos anti-cxcr3.
WO2010138393A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
PH12016500136B1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
WO2010138387A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2010138392A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
MX2010007810A (es) Coposicion que contiene capsicum para tratar un trastorno de la piel.
HK1223632A1 (zh) 靶向的酶化合物及其用途
PH12014500057A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
WO2010138389A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin